Saline Solution for Injection
DrugIntravenous (IV)
NCT Number: NCT01280344
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Phase 2
Florence, Alabama, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous (IV)
Intravenous (IV)
Time frame: Up to 10 days
To assess the efficacy of three repeated dose levels of ipamorelin vs. placebo
Time frame: Up to 10 days or until hospital discharge
To investigate the effect of ipamorelin on ancillary efficacy measures of GI function and recovery
Time frame: 14 day outpatient follow-up visit
To investigate the safety and tolerability of ipamorelin laboratory and clinical parameters, incidence of adverse events, until hospital discharge, 14-day outpatient follow-up visit, or until resolution of adverse events
Helsinn Therapeutics (U.S.), Inc
Industry
Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04880538
Gastrointestinal Dysmotility
Baltimore, Maryland, United States
View Trial DetailsNCT01285570
Gastrointestinal Dysmotility
Fountain Valley, California, United States
View Trial DetailsNCT01296620
Gastrointestinal Dysmotility
Glendale, California, United States
View Trial Details